Scientists hunt for biomarkers to personalize proton beam cancer therapy

NCT ID NCT04367779

Completed Knowledge-focused Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study enrolled 84 people with brain tumors, meningioma, or high-grade sarcoma who received proton beam therapy. Researchers analyzed tumor and blood samples to find biomarkers that might predict how well the cancer responds to treatment. The goal is to eventually help doctors choose the best therapy for each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: proton beam therapy
What this could lead to: If successful, this could help doctors predict which patients will benefit most from proton beam therapy, personalizing cancer treatment.
What could go wrong: This is an observational study, not a treatment trial. It may not find reliable biomarkers, and results may not change clinical practice soon.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm meningioma neoplasm sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN CANCER MENINGIOMA SARCOMA

Contacts and locations

Locations

Centre Antoine Lacassagne

Nice, 06189, France
Centre Léon Bérard

Lyon, 69008, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.